|Hikma Pharmaceuticals PLC -- USA Stock|| |
USD 14.06 1.04 6.89%
Founder and Honorary Life Pres
We currently do not have informatin regarding HE Darwazah. This executive tanure with Hikma Pharmaceuticals PLC is not currenlty determined.
(44) 20 7399 2761 www.hikma.com
The company has return on total asset (ROA)
of 4.71 %
which means that it generated profit of $4.71 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE)
of 6.97 %
meaning that it generated $6.97 on every $100 dollars invested by stockholders.
The company has accumulated 880 M in total debt with debt to equity ratio (D/E) of 35.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Hikma Pharmaceuticals PLC has Current Ratio of 1.86 which is within standard range for the sector.
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of branded and nonbranded generic and inlicensed pharmaceutical solutions in solid, semisolid, liquid, and injectable final dosage forms in the Middle East and North Africa, the United States, Europe, the United Kingdom, and internationally. Hikma Pharmaceuticals PLC (HKMPF) is traded on OTC Market in USA. It is located in 13 Hanover Square, London W1S 1HW, United Kingdom and employs 7,189 people.